Biochemical discordance of a urinary fluoroquinolone-resistant Escherichia coli ST1193 as a Shigella species: A case report
Abstract
Escherichia coli (E. coli) sequence type 1193 (ST1193) is an emerging pathogenic organism that is increasingly identified in urinary specimens and often demonstrates multi-drug resistance. Although ST1193 is a well-documented E. coli clone, its lactose-nonfermenting phenotype and other atypical biochemical features may complicate routine laboratory interpretation. We report a urinary isolate from a 38-year-old woman with asymptomatic bacteriuria and a history of recurrent urinary tract infections that was identified as E. coli by MALDI-TOF mass spectrometry and confirmed as E. coli ST1193 by whole-genome sequencing but was classified as Shigella group with 91% confidence by an automated biochemical identification panel. The isolate demonstrated delayed growth as pinpoint pale-tan colonies on CHROMagar, non-lactose fermentation on MacConkey agar, lysine decarboxylase positivity, and orange-yellow colony formation on Hektoen Enteric agar. Antimicrobial susceptibility testing demonstrated resistance to ampicillin, some 1st and 2nd generation cephalosporins, and fluoroquinolones, with susceptibility to nitrofurantoin, trimethoprim-sulfamethoxazole, later-generation cephalosporins, piperacillin-tazobactam, aminoglycosides, and carbapenems. This case highlights a practical diagnostic pitfall. E. coli ST1193 may be accurately identified by MALDI-TOF MS and genomic methods yet still generate misleading biochemical-panel results suggestive of Shigella due to their similar genomic…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.